Urinary neopterin, an indicator of systemic immune activation, is increased in most patients with epithelial ovarian carcinoma (EOC) and is an independent prognostic indicator. The data on prognostic significance of neopterin in EOC have been collected before the advent of paclitaxel that has changed the management and natural history of the disease. In the present study, wc have evaluated the prognostic significance of urinary neopterin in 49 patients with primary and secondary ovarian neoplasms treated in the late 1990s and in 2000s. Urinary neopterin was measured by high-performance liquid chromatography. Compared to controls, urinary neopterin was significantly increased in patients with both primary ovarian cancer and ovarian metastases of other tumors (341 ± 343, and 328 ± 277 vs. 133 ± 40 μηιοΐ/mol creatinine; ρ <0.001 ). Serious toxicity of chemotherapy was observed in 8 out of 12 (67%) patients with urinary neopterin equal or above 338 μπιοΐ/ιτιοί creatinine (mean of all patients) compared to 2 of 19 ( 11%) of patients with urinary neopterin below 338 μηιοΐ/ηιοί creatinine (Fisher cxact test, ρ -0.001). No significant changes were observed in urinary neopterin concentrations during the treatment with paclitaxel/platinum. A significant correlation was observed between urinary neopterin and percentage of xylose absorbed (r s = -0.58, ρ = 0.03), and positive correlations were observed between urinary neopterin and lactulose/mannitol (r s = 0.63, ρ = 0.02), lactulose/xylose (r s = 0.79, ρ = 0.0007) and sucrose/xylose (r s = 0.60, ρ = 0.02) ratios. Survival was significantly longer in patients with urinary neopterin below 338 μιηοΐ/ιτιοί creatinine in the whole group of 49 patients with ovarian cancer, in 36 patients with primary ovarian canccr as well as in 13 patients in ovarian metastases of other primary tumors. A significant difference in survival was also observed when 37 pretreated patients or 24 pretreated EOC patients were evaluated (p = 0.05). In conclusion, neopterin remains a significant prognostic indicator in patients with recurrent ov arian cancer in the era of newer chemotherapeutic agents. Increased urinary neopterin was associated with chemotherapy toxicity.
Introduction
Epithelial ovarian carcinoma (EOC) represents the leading cause of mortality for gynecological cancer ( 1 ) . The high mortality rate of EOC reflects the difficulty in early diagnosis. Despite aggressive surgery and chemotherapy, most patients with advanced disease will ultimately relapse and die. On the other hand, the survival of EOC patients has improved substantially over the recent decades. Combination of platinum derivatives (cisplatin or carboplatin) with paclitaxel currently represents the standard front line regimen for patients with advanced disease after demonstration of superior survival in randomized clinical trials (2, 3) , and new therapeutic options have emerged in patients with recurrent disease.
Neopterin is an unconjugated pteridine synthesized from guanosine triphosphate (4) . Human monocytesderived macrophages produce significant quantities of neopterin when stimulated with interferon-γ (5), and measurement of neopterin concentrations is used for the assessment of macrophage activation. Similarly to tumors of other primary locations, increased urinary and serum ncopterin concentrations have been reported in patients with gynecological cancers, including EOC, cervical carcinoma, endometrial carcinoma, uterine Melichar Β. et αι.: Neopterin in Ovarian Cancer sarcomas, and vulvar carcinoma, but, in general, not in women with benign neoplasms or precancerous disorders (6) . The ovaries are also site of metastatic spread from tumors of other sites, mostly gastrointestinal and breast carcinomas (7) . The prevalence of increased urinary neopterin concentrations is high in EOC (Tabie 1), but substantially lower percentages of patients with breast (8) , colorectal (9) , or gastric ( 10) carcinomas and urinary neopterin concentrations above normal have been reported ( Table 2) .
As is the case in many tumors of other primary locations, it has been demonstrated that increased urinary neopterin is a negative prognostic factor in patients with EOC (11, 12) . However, the studies on prognostic significance were performed before the advent of paclitaxel. The natural history of EOC has changed in recent decades as a consequence of increased efficacy of first line treatment as well as of availability of other therapeutic options in patients with recurrent disease. Because of increased patient survival, metastases in hitherto rare locations, e.g. brain, have become increasingly common (13) . Most patients ultimately present with recurrent disease, but less is known about the prognostic significance of urinary neopterin in this group of patients (14) . The effect of paclitaxel/platinum chemotherapy on urinary neopterin was also examined in selected patients. We also addressed the question whether measurement of urinary neopterin could be helpful in distinguishing primary and secondary ovarian neoplasms. Correlation between urinary neopterin and laboratory parameters of intestinal permeability was also studied.
Material and Methods

Patients
The present study was a retrospective analysis of urinary neopterin measurements collected in 49 patients, aged 57+13 (range 26 -81 ) years with ovarian cancer treated at the Charles University Medical School Teaching Hospital. Thirty-six patients had primary ovarian cancer, among them 32 patients had epithelial ovarian carcinoma (EOC) and 4 patients had other primary ovarian tumors (3 patients with granulosa cell tumor and 1 patient with ovarian stromal sarcoma), and 13 patients had metastatic ovarian cancer: colorectal carcinoma 8 patients, gallbladder carcinoma 2 patients, gastric carcinoma, breast carcinoma, and mucinous peritoneal cystadenocarcinoma (pseudomyxoma peritonei) one patient each. In addition to ovarian primary, 9 EOC patients had a history of other primary cancers (breast carcinoma 7 patients, pancreatic carcinoma and gastrointestinal stromal tumor one patient each). Twelve patients were chemotherapynaive and 37 patients had been previously treated with chemotherapy. Sixteen apparently healthy women, aged 52 ± 9 (range 37 -75) years, were included as controls.
Urinary neopterin determination Morning urine specimens were collected and stored at -20°C until analysis. Urinary neopterin was measured by high-performance liquid chromatography. Briefly, after centrifugation (5 minutes, 1300 g) and diluting 100 μΙ of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, samples were injected onto a column, and neopterin was determined using high performance liquid chromatography systems LC1084A (HewlettPackard, Palo Alto, USA) with HP 79850 A integrator (Hewlett-Packard) or Prominence LC20 (Shimadzu, Kyoto, Japan) as described (15) . Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of the sample 1:50 (v/v) on a Hitachi 716 analyser (Tokyo, Japan) using a commercial kit (Boehringer, Mannheim, Germany) according the manufacturer's instructions, and neopterin concentrations were expressed as neopterin/creatinine ratio (pinol/mol creatinine).
Measurement of intestinal
permeability In 14 patients evaluated before the start of therapy, intestinal permeability was studied by measuring urinary sucrose, lactulose, D-xylose and mannitol after oral challenge (16) . Briefly, after an overnight fast, a pretest urine sample was collected to detect any endogenous mannitol and the patients ingested 100 ml of the test solution containing 2 g of mannitol, 2 g of xylose, 10 g of lactulose, and 25 g of sucrose in water. The patients then continued fasting for 2 hours, and urine was collected for 5 hours. Lactulose, xylose, sucrose and mannitol were determined by capillary gas chromatography, and urinary cxcretion was expressed as percentage of the ingested dose as well as the ratio of lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose.
Sta tis ti cal a nah 's is
Urinary neopterin concentrations of patients and controls were compared by Mann-Whitney U test, neopterin before and during therapy was compared by Wilcoxon signed rank test, and correlations were investigated by Spearman's rank correlation. The proportions of patients with or without complications were compared by Fisher exact test. The survival was measured from the time of sample collection to death or last follow-up. No patients were lost to follow-up, and the last visit of surviving patients was during 2006. The survival of patients was analyzed by the KaplanMeier method, and survival of different groups of patients was compared by log-rank test. The decision on statistical significance was based on ρ = 0.05 significance level. The analyses were performed using NCSS 2001 software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
Compared to controls, urinary neopterin was significantly increased in patients with ovarian cancer (mean ± standard deviation: 338 ± 324, range 41 -1980, vs. 133 ± 40, range 80 -229 μιηοΐ/mol creatinine, ρ < 0.0001; Figure 1 ). No statistically significant differwell as in ovarian metastases of other primaries (p < 0.002). Urinary neopterin concentrations above 213 μτηοΐ/mol creatinine (mean + 2 standard deviations of controls) were observed in 22 (61%) of patients with primary ovarian canccr and 6 (46%) of patients with ovarian metastases, and the difference in frequency of increased neopterin concentrations was not statistically significant. Among patients with primary ovarian cancer, no statistically significant difference was noted between 32 patients with EOC and 4 patients with patients with urinary neopterin equal or above 338 μπιοΐ/ηιοί creatinine (mean of all patients) compared to 2 of 19 (11%) of patients with urinary neopterin below 338 μιηοΐ/mol creatinine (Fisher exact test, ρ -0.001). Twenty patients were evaluated before and during the therapy with paclitaxel/platinum combination chemotherapy. Compared to pretreatment neopterin (268 ± 197, range 41 -930 μιηοΐ/mol creatinine), no significant changes were observed in urinary neopterin concentrations one week after the first dose (330 ± 260, range 97 -1127 μπιοΐ/mol creatinine), at the end of first or second cycle (314 ± 302, range 106 -1393 μιηοΐ/ιηοΐ creatinine), or at two subsequent visits 57 ± 22 days and 86 ± 35 days after the start of therapy (200 ± 164. range 48 -665, and 187 ± 89, range 55 -311 μιηοΐ/ιηοΐ creatinine). In 14 patients in whom intestinal permeability and urinary neopterin were determined simultaneously, significant negative correlation was observed between urinary neopterin and percentage of xylose absorbed (r s = -0.58, ρ = 0.03), and positive correlations were observed between urinary neopterin and lactulose/mannitol ratio (r s = 0.63, ρ = 0.02), lactulose/xylose ratio (r s = 0.79, ρ < 0.001; Figure 3 ) and sucrose/xylose ratio (r s = 0.60, ρ = 0.02). The corréla-tion between neopterin and sucrose/mannitol ratio was of borderline significance (r s = 0.52, ρ = 0.06).
Survival was significantly longer in patients with urinary neopterin below 338 μιηοΐ/mol creatinine in the whole group of 49 patients with ovarian cancer (median survival 31 vs. 11 months, ρ = 0.003), in 36 patients with primary ovarian cancer (median 58 vs. 11 months, ρ -0.02; Figure 4 ) as well as in 13 patients in ovarian metastases of other primary tumors (median 27 vs. 8 months, ρ = 0.05, Figure 5) . A significant difference in survival was also observed when only 37 pretreated patients (median 31 vs. 11 months, ρ = 0.01 ) or 24 pretreated EOC patients (median 58 vs. 20 months, ρ -0.05) were evaluated. The trend of longer survival of untreated patients with urinary neopterin below 338 μιτιοΐ/mol creatinine was of borderline significance (median 54 vs. 29 months, ρ = 0.09). In contrast, the difference in survival between primary and 
Discussion
The observation of increased urinary neopterin in patients with ovarian cancer in the present study is in agreement with previous reports. Urinary or serum neopterin has been investigated in patients with gynecological malignancies in a number of studies (6) , and neopterin was found to be increased in a substantial percentage of patients with ovarian, cervical, endometrial and vulvar carcinomas, and in uterine sarcomas. Neopterin concentrations were, in general, reported to be within normal limits in patients with benign tumors or precancerous disorders (17) . Increased neopterin concentrations were limited to patients with active disease, and normal neopterin levels were reported in patients without evidence of disease activity (18) (19) (20) (21) (22) .
Most of these studies included, partly or exclusively, patients with ovarian cancer, predominantly EOC (Table 1 ). In EOC, higher neopterin was associated with advanced stage (12, 14) . Other studies have shown that increased neopterin is associated with inferior survival (11, 12, 14) and increased risk of progression (23) . Increased urinary neopterin was associated with the prcscncc of disease at second look surgery (14) , and urinary neopterin concentrations at the time of second-look surgery were predictive of survival. Increased neopterin concentrations were associated with poor prognosis in patients with no or minimal residual disease at second look surgery, but not in patients with macroscopic tumors (22) . An association has been detected between the course of the disease and neopterin levels. Neopterin concentrations decreased after successful therapy, but increased during disease progression and were elevated before death (14, 17, 24, 25) .
In addition to what has already been reported on urinary neopterin in ovarian cancer, we have found that urinary neopterin is also increased in ovarian metastases of other primary tumors. The percentage of patients with increased urinary neopterin reported in EOC seems to be substantially higher than in many tumors of other locations (Table 2) . We therefore originally hypothesized that urinary neopterin could be helpful in distinguishing primary and secondary ovarian tumors. However, the means of urinary neopterin concentrations in primary and secondary ovarian tumors were similar, and the percentages of patients with increased neopterin concentrations were not sig- (7), but the prognosis of patients with metastatic ovarian cancer seems to be worse than in primary ovarian tumors (26, 27) . In the present cohort, a relatively high proportion of EOC patients had a history of other primary (mostly breast carcinoma), but urinary neopterin was not different between EOC patients with or without a second primary neoplasm. The difference in survival between primary and metastatic ovarian tumors in the present study was not significant, probably because of the limited size of the cohort, but prognostic significance of increased urinary neopterin concentrations could be demonstrated even in a relatively small group of patients with ovarian metastases of other primary tumors. Present data also demonstrated that urinary neopterin is a significant prognostic factor in pretreated patients (mostly with recurrent disease). Previous studies on prognostic significance of neopterin in EOC were performed mostly during 1980s in chemotherapy-naive patients, before the advent of taxanes, topotecan, or gemcitabine, and present data indicate that neopterin remains a significant prognostic indicator in patients with recurrent disease treated with newer generation of therapeutic agents.
An increase in neopterin production has been documented after systemic administration of different cytokines (6) . Both paclitaxel and cisplatin have been shown to activate macrophages in vitro (28, 29) . Recently, we have reported an increase in urinary neopterin in breast cancer patients treated with the combination of paclitaxel and doxorubicin (8) . However, in the present study we did not observe an increase in urinary neopterin after paclitaxel/platinum chemotherapy. Urinary neopterin was increased in the majority of patients. Reduction of the tumor burden resulted in lower neopterin in patients with increased baseline neopterin concentrations, as has been reported earlier (25) , and this decrease might offset any increase induced by activation of macrophages by paclitaxel or platinum. On the other hand, increased urinary neopterin was associated with substantially higher risk of the toxicity of chemotherapy. This observation could be explained by the alterations of the metabolism of cytotoxic drugs that accompany systemic inflammatory response (30) . In an earlier study, we have observed higher pretreatment neopterin concentrations in colorectal carcinoma patients treated with irinotecan who subsequently experienced toxicity (9) , and the data from the present study corroborate these results.
In earlier studies, correlations were observed in ovarian cancer patients between neopterin and other indicators of inflammatory or immune activation, e.g. erythrocyte sedimentation rate (14) , concentrations of soluble interleukin-2 receptor (II), or variants of soluble CD44 molecule (3 1 ). In the present study, a correlation was observed between urinary neopterin and alterations of intestinal permeability. An association between systemic immune activation, reflected in increased neopterin concentrations, and disturbances of laboratory parameters of intestinal permeability has been reported in human immunodeficiency virus infection (32) , and the present study extends this phenomenon to cancer patients. Laboratory parameters of intestinal permeability (e.g. lactulose/mannitol ratio) are increased in chemotherapy-naive cancer patients (33, 34) , and increase further during therapy (35) . The increase of intestinal permeability could be caused by malnutrition (36) . Low serum albumin, an important laboratory marker of malnutrition, results from systemic inflammatory response, and, similarly to increased neopterin, low serum albumin was shown to represent an indicator of poor prognosis in EOC (37, 38) .
We conclude that, in agreement with earlier studies, increased urinary neoptcrin is found in patients with ovarian cancer, both primary ovarian cancer and ovarian metastases of other tumors. Increased urinary neopterin was associated with treatment toxicity and was predictive of poor prognosis, but no significant change of neopterin concentrations was observed during the therapy with paclitaxel/platinum combination. A correlation has been observed between urinary neopterin and parameters of intestinal permeability. Neopterin remains a significant prognostic indicator in patients with recurrent ovarian cancer in the era of newer chemotherapeutic agents.
